Date Filed | Type | Description |
08/21/2023 |
13F-HR/A
| Form 13F-HR/A - Quarterly report filed by institutional managers, Holdings: [Amend] |
08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
07/03/2023 |
SC 13G
| Affinity Asset Advisors, LLC reports a 9.2% stake in Aeglea Biotherapeutics, Inc. |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
08/12/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
05/13/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
05/09/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/11/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
11/22/2021 |
SC 13G
| Affinity Asset Advisors, LLC reports a 5.1% stake in Vincerx Pharma, Inc. |
11/12/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
08/13/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
05/14/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
02/12/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |